Aglip™ 25 Tablet: Each tablet contains Alogliptin Benzoate INN equivalent to Alogliptin 25 mg.
Aglip™ 12.5 Tablet: Each tablet contains Alogliptin Benzoate INN equivalent to Alogliptin 12.5 mg.
Aglip™ is Alogliptin preparation which is a dipeptidyl peptidase (DPP)-4 inhibitor thus inhibits DPP-4 and activate GLP-1 to increase insulin production and decrease glucagon secretion. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the glipin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity.
Limited data with alogliptin in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy.
No adverse developmental effects were observed when alogliptin was administered to pregnant rats and rabbits during organogenesis at exposures 180 and 149-times the 25 mg clinical dose, respectively, based on plasma drug exposure.
There is no information regarding the presence of alogliptin in human milk, the effects on the breastfed infant, or the effects on milk production. Alogliptin is present in rat milk; however, due to species specific differences in lactation physiology, animal lactation data may not reliably predict levels in human milk.
Store at or below 30°C temperature. Keep away from light and wet place. Keep out of reach of children.